Beyond affinity: AI-supported developability assessment and multi-objective optimization in antibody development
Antibody Therapeutics · 01.10.2026 · 9 (4) · 508-520
DOI: 10.1093/abt/tbag039 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Antibody Therapeutics, online erschienen am 31.07.2026. Verfasst von Qianhui Jiang und 6 weiteren Autor:innen. Beteiligte Einrichtung: Division of Applied Oral Sciences and Community Dental Care, Faculty of Dentistry, The University of Hong Kong, 34 Hospital Road, Hong Kong SAR, Chin…. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 102 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Collaborative Research Fund of Research Grants Council, collaborative research, basic research.
Abstract (Originalsprache)
Therapeutic antibodies are a major class of medicines, but high target affinity alone does not ensure manufacturability, stability, safety, or clinical success. Developability has therefore become a central constraint in antibody engineering and has pushed the field beyond affinity-first screening toward multi-objective decision-making. Machine-learning-based models increasingly integrate antibody sequence, structure, interaction, and assay data to estimate properties such as affinity, specificity, aggregation, viscosity, solubility, stability, immunogenicity, and pharmacokinetics before experimental testing. In practice, these models are most useful when they help prioritize experiments rather than replace empirical evaluation. Here, we review the data resources used for antibody developability modeling, the main classes of property predictors, and optimization frameworks that balance competing design objectives. We cover Pareto optimization, Bayesian optimization, active learning, and conditional generative modeling, and discuss how these approaches are being adapted to bispecific antibodies and nanobodies. We argue that AI is most useful when model outputs are interpreted in the context of assay design, uncertainty, and antibody format, and when they are used to guide candidate selection and experimental design rather than serve as stand-alone surrogates for developability.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Division of Applied Oral Sciences and Community Dental Care, Faculty of Dentistry, The University of Hong Kong, 34 Hospital Road, Hong Kong SAR, China.
- Division of Periodontology & Implant Dentistry, Faculty of Dentistry, The University of Hong Kong, 34 Hospital Road, Hong Kong SAR, China.
ORCID-Profile: Qianhui Jiang, Junwen Wang
Förderung
- Collaborative Research Fund of Research Grants Council
- collaborative research
- basic research
- University of Hong Kong, and startup funds
- Faculty of Dentistry, the University of Hong Kong
Zitieren
APA
Jiang, Q., Guan, J., Yu, D., Singh, P., Pelekos, G., Lo, E. C. M., & Wang, J. (2026). Beyond affinity: AI-supported developability assessment and multi-objective optimization in antibody development. Antibody Therapeutics, 9(4), 508-520. https://doi.org/10.1093/abt/tbag039
Vancouver
Jiang Q, Guan J, Yu D, Singh P, Pelekos G, Lo ECM, et al. Beyond affinity: AI-supported developability assessment and multi-objective optimization in antibody development. Antibody Therapeutics. 2026;9(4):508-520. doi:10.1093/abt/tbag039
BibTeX
@article{Jiang2026,
author = {Jiang, Qianhui and Guan, Jiahui and Yu, Dan and Singh, Pradeep and Pelekos, George and Lo, Edward Chin Man and Wang, Junwen},
title = {Beyond affinity: AI-supported developability assessment and multi-objective optimization in antibody development},
journal = {Antibody Therapeutics},
year = {2026},
volume = {9},
number = {4},
pages = {508--520},
doi = {10.1093/abt/tbag039}
}
EUVIMED